Wolverine Asset Management’s Pacira BioSciences PCRX Stock Holding History

Wolverine Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,200	Closed	-$649K	–	1817
2025 Q3	$649K	Hold	25,200	–	–	﹤0.01%	817
2025 Q2	$602K	Hold	25,200	–	–	0.01%	834
2025 Q1	$626K	Sell	25,200 -400	-2%	-$9.58K	0.01%	804
2024 Q4	$482K	Hold	25,600	–	–	﹤0.01%	874
2024 Q3	$385K	Sell	25,600 -100	-0.4%	-$1.71K	﹤0.01%	919
2024 Q2	$735K	Buy	+25,700	New	+$731K	0.01%	754
2021 Q2	–	Sell	-29,000	Closed	-$2.03M	–	2348
2021 Q1	$2.03M	Hold	29,000	–	–	0.02%	424
2020 Q4	$1.74M	Buy	+29,000	New	+$1.7M	0.01%	492
2018 Q4	–	Sell	-9,400	Closed	-$462K	–	1726
2018 Q3	$462K	Sell	9,400 -5,000	-35%	-$216K	0.01%	1037
2018 Q2	$461K	Sell	14,400 -17,000	-54%	-$587K	0.01%	958
2018 Q1	$978K	Buy	31,400 +23,000	+274%	+$819K	0.01%	775
2017 Q4	$383K	Buy	+8,400	New	+$333K	﹤0.01%	959
2017 Q1	–	Sell	-25,000	Closed	-$807K	–	1339
2016 Q4	$807K	Buy	+25,000	New	+$834K	0.01%	578
2013 Q3	–	Sell	-50	Closed	-$21K	–	2826
2013 Q2	$21K	Buy	+50	New	+$1.45K	﹤0.01%	1997

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Asset Management's PCRX Position: Q1 2026 in Review

Wolverine Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 3,000 shares — an estimated $77.6K sold.

Wolverine Asset Management first reported a position in PCRX in Q1 2022 and held it in 5 quarters. The position peaked at $798K in Q1 2022. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Wolverine Asset Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Wolverine Asset Management sold 3,000 Pacira BioSciences shares in Q1 2026, an estimated $77.6K.
Wolverine Asset Management first reported a position in Pacira BioSciences in Q1 2022 and held it in 5 quarters.
Wolverine Asset Management's Pacira BioSciences position peaked at $798K in Q1 2022.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.